BenzingaSeptember 22, 2026 at 6:34 AM NYLast Month
UBS Maintains Neutral on Amrize, Lowers Price Target to $42
UBS analyst Julian Radlinger maintains Amrize (NYSE:AMRZ) with a Neutral and lowers the price target from $57 to $42.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
